Related Experiment Video
Updated: Feb 10, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication
Verena Schildgen1, Jessica Lüsebrink1, Oliver Schildgen1
1Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln Ostmerheimer Str 200., Institut für Pathologie, D-51109 Köln (Cologne) Germany.
Background:
KRAS, BRAF, EGFR and ALK-mutation testing is a prerequisite for non-small-cell lung cancer treatments, but there remains limited epidemiological information about such mutations in German cohorts.
Materials & Methods:
Between February 2010 and June 2015, a total of 1080 tumor samples from 1019 non-small-cell lung cancer patients were analyzed for KRAS, BRAF, EGFR and ALK-mutations by Therascreen-pyrosequencing and FISH.
Results:
Mutation patterns differed dependent on the histological subtype and sex. Mainly, adenocarcinomas were mutated and formed the major histological group. Double mutations were observed also not explicitly screened for. In our German cohort, female adenocarcinoma patients had statistically significantly higher rates EGFR mutations than male patients.
Discussion:
The different mutation patterns dependent on histological phenotypes warrant further epidemiological studies while suggesting different mechanisms of cancerogenesis.
Related Concept Videos
Hospitals-II
Nurses that work in...
Indicators
Hospitals-I
Mutations
Tertiary Healthcare System
Cancers Originate from Somatic Mutations in a Single Cell

